Indapamide Pill for Secondary Progressive Multiple Sclerosis (SPMS)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Foothills Medical Centre, Calgary, Canada
Secondary Progressive Multiple Sclerosis (SPMS)+4 More
Indapamide Pill - Drug
Eligibility
18 - 65
All Sexes
Eligible conditions
Select

Study Summary

Hydroxychloroquine and Indapamide in SPMS

See full description

Eligible Conditions

  • Secondary Progressive Multiple Sclerosis (SPMS)

Treatment Effectiveness

Study Objectives

This trial is evaluating whether Indapamide Pill will improve 1 primary outcome and 5 secondary outcomes in patients with Secondary Progressive Multiple Sclerosis (SPMS). Measurement will happen over the course of Change in Timed 25-Foot Walk performance between the 6 month and 18 month visit.

Month 18
Timed 25-Foot Walk (T25FW)
Month 18
9-Hole Peg Test
Functional Systems and Expanded Disability Status Scale (EDSS)
Modified Fatigue Impact Scale (MFIS)
Multiple Sclerosis Quality of Life Scale 54 item version
Symbol Digit Modalities Test

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

1 Treatment Group

Hydroxychloroquine and Indapamide
1 of 1
Experimental Treatment

This trial requires 35 total participants across 1 different treatment group

This trial involves a single treatment. Indapamide Pill is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Hydroxychloroquine and IndapamideOral Hydroxychloroquine, 200mg BID Oral Indapamide, 2.5 mg OD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hydroxychloroquine Pill
2020
N/A
~200

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly baseline, 1 month follow-up, 6 months follow-up, 12 months follow-up, and 18 months follow-up for reporting.

Closest Location

Foothills Medical Centre - Calgary, Canada

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. You must have received 1 prior treatment for Secondary Progressive Multiple Sclerosis (SPMS) or one of the other 4 conditions listed above. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Written informed consent obtained
Men and women aged 18 and 60 years inclusive
With SPMS, according to current diagnostic criteria
Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive.
Screening timed 25-foot walk (average of two trials) of 9 seconds or more

Patient Q&A Section

What causes secondary progressive multiple sclerosis (spms)?

"The pathogenesis of primary progressive or relapsing-remitting multiple sclerosis is still unknown. Nonetheless, this study demonstrates that in secondary progressive multiple sclerosis, immunomodulatory therapies may be an effective option to prevent relapse, which is frequently associated with rapid progression." - Anonymous Online Contributor

Unverified Answer

What are the signs of secondary progressive multiple sclerosis (spms)?

"Secondary progressive MS is defined by progressive neurological loss over time, which leads to persistent disability, even when the course of the disease is relatively mild. The course of spms is similar to classical progressive MS, with lesions more often appearing at the onset of symptoms, expanding and worsening, and resulting in disability more quickly. Spms patients have poorer outcomes compared with patients in the classic form of MS, mainly due to reduced time to dissemination. We suggest that patients with spms need to be monitored carefully because of the risk of developing secondary progressive MS of their own, even when they do not have another clinical form of MS." - Anonymous Online Contributor

Unverified Answer

What is secondary progressive multiple sclerosis (spms)?

"It is important to understand the disease process, like remission and spoliation in both primary and secondary progressive multiple sclerosis, as such information, can help with the selection of treatment, to define the disease-free era as well as assessing treatment effects and to monitor disease progression. Patients with SPMS are the most difficult to treat in terms of progression and quality of life." - Anonymous Online Contributor

Unverified Answer

What are common treatments for secondary progressive multiple sclerosis (spms)?

"A limited number of treatments are available for RRMS and SPMS patients. Several treatments are useful for RRMS patients but only palliative care has a positive effect on QOL in SPMS." - Anonymous Online Contributor

Unverified Answer

Can secondary progressive multiple sclerosis (spms) be cured?

"The prognosis of secondary progressive MS can be improved by active treatment with a specific disease-modifying antirheumatic drug or immunomodulators. More recent experience confirms sustained remission after 3 to 12 years with such treatment." - Anonymous Online Contributor

Unverified Answer

How many people get secondary progressive multiple sclerosis (spms) a year in the United States?

"Results from a recent clinical trial indicates that the incidence of secondary progressive multiple sclerosis in the United States appears to be increasing with a significant proportion of individuals with secondary progressive multiple sclerosis under diagnosed or undertreated." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in indapamide pill for therapeutic use?

"New dosage forms are undergoing clinical trials, which will assist in the development of an improved, safer indapamide formulation for therapeutic use. Clinically, indapamide is a safer treatment option for MS, especially in secondary progressive MS patients with concomitant hypertension." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of secondary progressive multiple sclerosis (spms)?

"Overall only 18 out of the 743 cases of spms were familial. Of the other 506 cases, there were only 2 cases that could be linked to environmental factors, and 2 cases with unknown causes. In the familial cases there was a high susceptibility of presenting with the same clinical characteristics of spms, and a similar relapse rate as seen in the sporadic cases, showing that it could be the same disease. In any case, it is important to remember that in the epidemiology, spms is a multifactorial disease, and this must be taken into account when analyzing the results of any clinical or epidemiological study." - Anonymous Online Contributor

Unverified Answer

Is indapamide pill typically used in combination with any other treatments?

"Indapamide pill was frequently used in combination with other drugs in SPMS patients. Further studies are needed to investigate the influence of indapamide on other drugs' tolerability, efficacy and side effects." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating secondary progressive multiple sclerosis (spms)?

"Although no treatment has been proven to halt the progression of secondary progressive multiple sclerosis, the development of new treatments is ongoing. The following are some of these new treatments and their benefits:\n\n- Natalizumab is a monoclonal antibody therapy that binds to the α4 integrin subunit on T cells, interfering with their binding to their receptors. Results from three large randomized, placebo-controlled, double-blind trials demonstrated that natalizumab had a significant therapeutic effect on reducing relapses in patients with secondary progressive multiple sclerosis. Patients who take the drug experienced a 50% reduction in relapses versus patients who did not." - Anonymous Online Contributor

Unverified Answer

What is indapamide pill?

"Results from a recent paper, it was found that indapamide does not improve either the symptom profile or the cognitive functioning of patients with secondary progressive multiple sclerosis." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for secondary progressive multiple sclerosis (spms)?

"There is a lack of well-designed clinical trials for secondary progressive multiple sclerosis (spms). There is an urgent need for these clinical trials to improve the treatment for spms." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Secondary Progressive Multiple Sclerosis (SPMS) by sharing your contact details with the study coordinator.